In another study, patients with T2DM and nonalcoholic fatty liver disease treatment with semisynthetic derivative of CDCA led to enhanced serum FGF19 levels and improved insulin sensitivity39. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.